NEW YORK, NY / ACCESSWIRE / June 26, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Oncolytics Biotech Inc.
https://ub.rdinvesting.com/news/?ticker=ONC-TO

Spectral Medical Inc.
https://ub.rdinvesting.com/news/?ticker=EDT-TO

CRH Medical Corp.
https://ub.rdinvesting.com/news/?ticker=CRH-TO

ESSA Pharma Inc.
https://ub.rdinvesting.com/news/?ticker=EPI-TO

Oncolytics Biotech's stock moved 3.26% lower Friday, to close the day at $0.45. The stock recorded a trading volume of 417,564 shares, which was below its three months average volume of 438,278 shares. In the last year Oncolytics Bio's shares have traded in a range of 0.19 - 1.13. The share price has gained 134.21% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.68 is greater than its 200-day moving average of $0.52. Shares of Oncolytics Biotech have gained approximately 67.92 percent year-to-date.

Access RDI?s Oncolytics Biotech Research Report at:
https://ub.rdinvesting.com/news/?ticker=ONC-TO

On Friday, shares in Spectral Medical recorded a trading volume of 137,245 shares, which was below the three months average volume of 235,639 shares. The stock ended the day 1.11% lower at 0.45. The share price has gained 147.22% from its 52 week low with a 52 week trading range of 0.18 - 2.07.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $0.50 is greater than its 200-day moving average of $0.39. Shares of Spectral Medical have gained approximately 61.82 percent year-to-date.

Access RDI?s Spectral Medical Research Report at:
https://ub.rdinvesting.com/news/?ticker=EDT-TO

CRH Medical's stock moved 1.53% lower Friday, to close the day at $7.70. The stock recorded a trading volume of 186,174 shares, which was below its three months average volume of 516,484 shares. In the last year CRH Medical Corporation's shares have traded in a range of 4.48 - 12.35. The share price has gained 71.87% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $7.87 is below its 200-day moving average of $8.78. Shares of the company are trading at a Price to Earnings ratio of 63.11. Shares of CRH Medical have gained approximately 7.39 percent year-to-date.

Access RDI?s CRH Medical Research Report at:
https://ub.rdinvesting.com/news/?ticker=CRH-TO

On Friday, shares in ESSA Pharma recorded a trading volume of 48,900 shares, which was below the three months average volume of 54,700 shares. The stock ended the day 2.47% higher at 0.83. The share price has gained 16.90% from its 52 week low with a 52 week trading range of 0.71 - 4.60.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $2.13 is below its 200-day moving average of $2.81. Shares of ESSA Pharma have gained approximately 7.39 percent year-to-date.

Access RDI?s ESSA Pharma Research Report at:
https://ub.rdinvesting.com/news/?ticker=EPI-TO

Our Actionable Research on Oncolytics Biotech Inc. (TSX: ONC), Spectral Medical Inc. (TSX: EDT), CRH Medical Corp. (TSX: CRH) and ESSA Pharma Inc. (TSX: EPI) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com